HYDRALYTE_1170x120

Purdue Pharma

Purdue Pharma files for Chapter 11 under new settlement

Purdue Pharma files for Chapter 11 under new settlement

STAMFORD, Conn.— Purdue Pharma  announced on Sunday that it has filed for bankruptcy protection under the new agreement the company reached  in principle on a framework for settling the U.S. opioid litigation facing the company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs’ executive committee in the multidistrict litigation (MDL),

Purdue Pharma appoints Craig Landau as CEO

Purdue Pharma appoints Craig Landau as CEO

STAMFORD, Conn. — Craig Landau has been promoted to president and chief executive officer of Purdue Pharma L.P. With the move, Landau — who retains his duties as president and CEO of Purdue’s Canadian operations — takes the chief executive reins from Mark Timney, who the company said is leaving to pursue other career opportunities.

Purdue Pharma joins National Pharmaceutical Council

Purdue Pharma joins National Pharmaceutical Council

WASHINGTON — Purdue Pharma L.P. has become a member of health policy research group The National Pharmaceutical Council (NPC). NPC said Dr. Tracy Mayne, head of medical affairs strategic research at Purdue Pharma, will serve as the pharmaceutical company’s representative on the NPC board of directors. “NPC’s research and activities are helping to drive the discussion

Lupin releases Intermezzo generic in U.S.

Lupin releases Intermezzo generic in U.S.

BALTIMORE — Lupin Pharmaceuticals Inc., the U.S. arm of India-based Lupin Ltd., has launched the first product from its Gavis pipeline, zolpidem sublingual tablets 1.75 mg and 3.5 mg, an insomnia drug. Lupin said its product is a generic version of Intermezzo sublingual tablets (1.75 mg and 3.5 mg) from Purdue Pharma. The Lupin generic received